Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Articles Tagged With: cardiomyopathy

  • Clinical Features of Tachyarrhythmia-Induced Cardiomyopathy

    A prospective observational study of patients with left ventricular dysfunction without known cause and tachyarrhythmias has shown that restoration of sinus rhythm significantly improves left ventricular function in more than 80% of such patients by six months and, initially, normal left ventricular size can be predictive of this response.

  • Is Screening First-Degree Relatives of Cardiomyopathy Patients Worthwhile?

    An observational study of screening first-degree relatives of patients with dilated cardiomyopathy revealed 14% will show either dilated left ventricles, low left ventricular function, or both. These findings are more common if the relatives have been diagnosed with hypertension or are obese, but their frequency is not altered by sex or race.

  • Is Screening First-Degree Relatives of Cardiomyopathy Patients Worthwhile?

    An observational study of screening first-degree relatives of patients with dilated cardiomyopathy revealed 14% will show either dilated left ventricles, low left ventricular function, or both. These findings are more common if the relatives have been diagnosed with hypertension or are obese, but their frequency is not altered by sex or race.

  • Clinical and Genetic Characterizations to Diagnose Sarcoglycanopathies

    Sarcoglycanopathies, caused by various genetic mutations, may cause limb-girdle forms of muscular dystrophy early in life. Although there are no specific treatments for these disorders at this time, the clinical and genetic characterizations will assist in more precise diagnosis that will be critical to develop new molecular-based therapies.

  • Anti-parasitic Therapy of Chronic Chagas’ Cardiomyopathy

    Two thousand eight hundred fifty-four patients with Chagas’ cardiomyopathy were randomized to benznidazole or placebo, were treated for up to 80 days, and were followed for a mean of 5.4 years. Trypanocidal treatment with benznidazole reduced serum parasite detection but did not reduce clinical cardiac deterioration.